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X-linkedlymphoproliferativedisease,alsoknownasDuncan’ssyndrome,isararegeneticdisorderthatcausesexaggeratedimmune
responses to Epstein-Barr virus (EBV) infection and often leads to death. Patient presentation varies but can include signs and
symptoms typical of EBV, pancytopenia, and fulminant hepatitis.
1.CaseReport
A previously healthy 10-month-old boy was admitted with
one week of fever, rash, and malaise. He appeared lethargic
with a fever of 102 degrees F and a heart rate of 180 beats
per minute. He had a purpuric petechial rash over his trunk
and extremities and an erythematous bulging tympanic
membrane on the right. His liver was palpable 4cm below
the costal margin and he had no splenomegaly. His initial
white blood cell count was 3.9 with 68% lymphocytes and
13% atypical lymphocytes. His hemoglobin was 8.1mg/dL
and platelet count 36,000. His AST, ALT, and LDH were all
elevated at 152, 146, and 2041, respectively. Epstein-Barr
virus (EBV) serologies indicated acute infection and viral
load demonstrated persistent viremia. His immunoglobulins
were normal.
He was treated with ceftriaxone for acute otitis media
and possible bacteremia; over the next several days he
improved clinically with less lethargy and improved appetite.
However, his pancytopenia worsened necessitating red blood
cell and platelet transfusions. His bilirubin rose to 8, ALT
to 1890, and AST to 7300. His triglycerides were elevated
at 319 and ﬁbrinogen low at 107 (Table 1). A bone marrow
biopsy revealed hypocellular marrow with no evidence of
hemophagocytosis.
He was treated with high dose IVIG, acyclovir, steroids,
and chemotherapy according to the HLH-94 protocol [1].
Three weeks into his illness he developed respiratory distress
and was intubated. He developed progressive liver failure
with coagulopathy and appeared septic. He died 24 days after
theonsetofnonspeciﬁcviralsymptomsconsistentwithacute
EBV infection.
Gene sequencing performed on a peripheral blood
sample at the University of Washington identiﬁed a point
mutation in exon 1 resulting in a new splice site and the
deletion of 22 base pairs, frame shift, and early termination
of SH2D1A, conﬁrming a diagnosis of XLP. His mother is
a carrier of the mutation. His soluble interleukin-2 (sIL-
2R) receptor level was 9311U/mL and perforin studies were
normal. Natural killer cell function was not able to be
performed.
X-linked lymphoproliferative disease (XLP) is a rare
genetic disorder which aﬀects less than one in one million
people, usually previously healthy males in their ﬁrst decade
of life. The defective gene responsible for this disease is
found on the X chromosome at Xq25 and encodes the
protein SAP (signaling lymphocyte activation molecule or
SLAM-associated protein, also called DSHP or SH2D1A),
an important mediator of signal transduction in natural
killer (NK) and T cells that ultimately lead to lymphocyte2 Case Reports in Medicine
Table 1: Pertinent Lab Values.
On Admission
After
Treatment w/
antibiotics
White Blood
Cell
3.9K/µL
Lymphs 68%
Atypical Lymphs 13%
Hemoglobin 8.1g/dL
Platelets 36K/µL
Bilirubin 8mg/dL
ALT 146µ/L 1890µ/L
AST 152µ/L 7300µ/L
Triglycerides 319mg/dL
Fibrinogen 107mg/dL
LDH 2041µ/L
activation [2, 3]. More than 50 heterogeneous mutations of
SH2D1A have been reported, although none are identical
to that found in our patient. Deﬁciencies of this protein
alter the function of NK and T cells and decrease cytokine
production, subsequently aﬀecting B cell proliferation and
diﬀerentiation. This abnormal response renders the immune
system unable to destroy cells infected with EBV [4].
SAP also appears to enhance apoptosis in B and T
cells. Owing to the uncontrolled proliferation of T cells
in SAP deﬁcient patients, the majority of patients with
XLP will progress to fulminant infectious mononucleosis
with extensive hepatic necrosis and bone marrow failure
leading to death within one month of onset of the disease.
Survivors will typically exhibit residual cellular and humoral
immunodeﬁciency, and are at increased risk for additional
lymphoproliferative disorders and malignancies, usually of B
cell origin [4].
XLP classically presents as fever, marked lymphadenopa-
thy, malaise, pharyngitis, and hepatosplenomegaly. The
diagnosis should be suspected in young males with an
abnormal or exaggerated immune response to EBV, to
include prolonged clinical course of greater than 1-2 weeks,
marked cytopenias, viremia, or in those with a history
of fatal EBV infection in maternal male relatives. Initial
laboratory tests may reveal pancytopenia or lymphocytosis
on the CBC, atypical lymphocytes on peripheral blood
smear, positive Monospot or EBV titers, low ﬁbrinogen, and
elevation of bilirubin, triglycerides, and liver transaminases.
Immunoglobulin levels can also be helpful, as hypogam-
maglobulinemia occurs in one-third of patients. Serial labs
may demonstrate progressively worsening pancytopenias
and liver function tests. Subsequent evaluation with neu-
roimaging, coagulation studies, and bone marrow biopsy
can aid in determining the extent of disease. Deﬁnitive
diagnosisismadebyundergoinggenetictestingformutation
in SH2D1A.
XLP can have a similar clinical picture to hemophago-
cytic lymphohistocytosis (HLH) and in series of HLH
patients mutations in SAP are frequently found. Thus,
SAP mutation analyses should be considered in patients
with HLH without apparent cause [5–7]. HLH can be
familial in origin, or associated with various infections and
autoimmune disorders. NK function and perforin studies
can often be helpful in distinguishing these two entities;
patients with HLH will exhibit decreased NK cell activity
and perforin levels, while in XLP patients perforin levels
are usually normal. A diagnosis of HLH is conﬁrmed when
analysis of bone marrow aspirate or lymph node tissue
reveals hemophagocytosis [8].
The diﬀerential diagnosis of XLP also includes common
variable immunodeﬁciency (CVID), which aﬀects males and
females equally and is characterized by frequent respiratory
infections and low levels of IgG, IgA, and IgM [9]. Transient
hypogammaglobulinemia of infancy can occur in infants
without other complications and levels often normalize
after 24 months of age. Griscelli syndrome is an autosomal
recessive disease that features immunodeﬁciency, cytopenias,
partial albinism, neurologic deﬁcits, and viral induced HLH
[10]. Chediak-Higashi is another autosomal recessive syn-
drome featuring partial albinism and immunodeﬁciency, but
these patients also exhibit platelet dysfunction and can enter
a lethal phase of disease initiated by viral infection (often
EBV) leading to lymphohistiocytic inﬁltration of organs and
death [11]. It is important to distinguish these entities from
XLP as treatment approach and prognosis vary greatly.
Unfortunately, individuals with XLP who enter the
fulminant stage of disease have over 90% mortality, but
some improvement has been shown with the HLH-94
protocol consisting of steroids and cytotoxic drugs such
as cyclosporine and etoposide. Rituximab has reportedly
been eﬀective and IVIG has been used in the acute setting
with minimal beneﬁt. The only curative treatment for
patients with XLP is an allogeneic bone marrow transplant,
which ideally should be performed prior to EBV exposure.
Thus, perinatal testing with chorionic villus sampling or
amniocentesis is helpful in pregnancies of a known carrier
[12].
Primary care physicians should be aware of XLP and
suspect it in boys who develop complications with acute
EBV infections. With suspected cases, hematology and
immunology should be consulted for help in management
and diagnosis. While treatment for aﬀected children is still
largely ineﬀective, it is essential to make a diagnosis so
mothers who are carriers can receive appropriate genetic
counseling and other family members may be screened.
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